



doc 9/5

V. Portner 1645

RECEIVED

SEP 19 2001

1645

#11

TECH CENTER 1600/2900

PATENT

ATTORNEY DOCKET NO. 06132/054001

Certificate of Mailing: Date of Deposit: September 14, 2001

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Susan M. Barry

Printed name of person mailing correspondence

Susan M. Barry

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bruno Guy et al.

Art Unit: 1645

Serial No.: 09/423,042

Examiner: V. Portner

Filed: October 29, 1999

Customer No.: 21559

Title: Anti-Helicobacter Vaccine Composition for Use by the Subdiaphragmatic Systemic Route, and Combined Mucosal/Parenteral Immunization Method

Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL OF EXECUTED DECLARATION

Enclosed is an executed copy of the Declaration under 37 C.F.R. § 1.132 that was filed in unexecuted form in connection with the above-captioned patent application on August 28, 2001.

Although no charges are believed to be due, if there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: September 14, 2001

Susan M. Michaud
Susan M. Michaud, Ph.D.
Reg. No. 42,885

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045
06132.054001 reply to office action.doc



21559

PATENT TRADEMARK OFFICE


RECEIVED

SEP 19 2001

TECH CENTER 1600/2900

PATENT

ATTORNEY DOCKET NO. 06132/054001

Certificate of Mailing: Date of Deposit: September 14, 2001

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Susan M. Barry

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bruno Guy et al.

Art Unit: 1645

Serial No.: 09/423,042

Examiner: V. Portner

Filed: October 29, 1999

Customer No.: 21559

Title: Anti-Helicobacter Vaccine Composition for Use by the Subdiaphragmatic Systemic Route, and Combined Mucosal/Parenteral Immunization Method

Assistant Commissioner for Patents
Washington, D.C. 20231

DECLARATION UNDER 37 C.F.R. § 1.132

I declare:

1. I am an inventor of the subject matter that is described and claimed in the above-captioned patent application.

2. I currently hold the position of Director of Clinical Research at Acambis, Inc., which is an owner of this application and where I have been working for over ten years.

3. Experiments were carried out at Acambis to determine the efficacy of a mucosal prime, parenteral boost regimen in the prophylaxis of Helicobacter infection. Groups of ten, six to eight week old female Swiss-Webster (Taconic) mice were immunized by the mucosal prime, parenteral boost regimens summarized in the enclosed table. As is shown in the enclosed graph, the results of these experiments show that these regimens have prophylactic efficacy, with several antigens, as indicated.

4. All statements made herein of my own knowledge are true, and all statements made on information and belief are believed to be true; further these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Date:

9/5/2001

Cynthia K. Lee, Ph.D.

Animal Experiment Form




Experiment title: Evaluation of CLASS I antigens using a rectal mucosal prime/parenteral boost regimen

Objectives: Compare efficacy of CLASS I antigens using a rectal mucosal prime (LT) / parenteral boost (Alum) immunization regimen
Animal model: 6-8 wk. old, female, Swiss-Webster mice (Taconic).

Schedule and Design:				Route	Schedule	Post-imm. samples	Challenge	Sac
Group	# Mice	Dose antigen	Dose adjuvant (P-prime; B-boost)					
1	10	rUre (25 µg)	LT (500 ng)	Rectal	d. 0, 21, 42	d. 53 (blood)	d. 56 (1 x 10 ⁷ X47-2AL)	d. 84 (Gast. urease, culture, histology)
2	10	rUre (25 µg) P (10 µg) B	P: LT (500 ng) B: Alum (200 µg)	Rectal SC (back)	d. 0 d. 21, 42	"	"	"
3	10	rAlpA (25 µg) P (10 µg) B	"	"	"	"	"	"
4	10	r32K (25 µg) P (10 µg) B	"	"	"	"	"	"
5	10	rKata (25 µg) P (10 µg) B	"	"	"	"	"	"
6	10	rHspA (25 µg) P (10 µg) B	"	"	"	"	"	"
7	10	GHPO525 (25 µg) P (10 µg) B	"	"	"	"	"	"
8	10	GHPO536 (25 µg) P (10 µg) B	"	"	"	"	"	"
9	10	GHPO639 (25 µg) P (10 µg) B	"	"	"	"	"	"

10	10	GHPO792 (25 µg) P (10 µg) B	"	"	"	"	"	"	"
11	10	GHPO1320 (25 µg) P (10 µg) B	"	"	"	"	"	"	"
12	10	r76K (25 µg) P (10 µg) B	"	"	"	"	"	"	"
13	10	GHPO1615 (25 µg) P (10 µg) B	"	"	"	"	"	"	"
14	10	None	None	"	"	"	"	"	"

Exp. 203: Comparative efficacy of Class I antigens using a rectal mucosal prime/parenteral boost regimen



— Arithmetic mean